# Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

> **NCT05797168** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 506 (estimated)

## Conditions studied

- Ovarian Cancer
- Lung Adenocarcinoma
- Endometrial Cancer

## Interventions

- **DRUG:** AZD5335
- **DRUG:** Saruparib (AZD5305)
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** AZD9574

## Key facts

- **NCT ID:** NCT05797168
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2028-01-06
- **Final completion:** 2028-01-06
- **Target enrollment:** 506 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797168, "Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05797168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*